OTCMKTS:PURE PURE Bioscience (PURE) Stock Price, News & Analysis $0.07 -0.01 (-9.71%) As of 10/14/2026 01:17 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About PURE Bioscience Stock (OTCMKTS:PURE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PURE Bioscience alerts:Sign Up Key Stats Today's Range$0.07▼$0.0850-Day Range$0.06▼$0.0952-Week Range$0.04▼$0.10Volume8,025 shsAverage Volume39,568 shsMarket Capitalization$8.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PURE Bioscience, Inc. develops and commercializes antimicrobial products based on its proprietary silver dihydrogen citrate (SDC) technology. SDC is designed to provide broad-spectrum antimicrobial activity while serving as the active ingredient in disinfecting, sanitizing, and hygiene formulations. The company’s product portfolio has included PURE-branded solutions for hard-surface disinfection and sanitation, as well as applications in food safety, commercial and industrial settings, healthcare, and other environments where microbial control is important. Its products are intended for use on surfaces, equipment, and other areas requiring cleaning and antimicrobial protection. PURE Bioscience has historically marketed its products in the United States and has pursued additional commercial opportunities through distributors and strategic partners. The company is headquartered in California. Information about its current leadership and geographic operations is limited and may change over time.AI Generated. May Contain Errors. Read More PURE Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScorePURE MarketRank™: 0.370492234795 of 5 starsPURE Bioscience scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for PURE Bioscience. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PURE Bioscience is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PURE Bioscience is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of PURE Bioscience has been sold short.Short Interest Ratio / Days to CoverPURE Bioscience has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PURE Bioscience has recently increased by 15.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPURE Bioscience does not currently pay a dividend.Dividend GrowthPURE Bioscience does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentPURE Bioscience has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for PURE Bioscience this week, compared to 0 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PURE Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders35.56% of the stock of PURE Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPURE Bioscience has minimal institutional ownership at this time.Read more about PURE Bioscience's insider trading history. Receive PURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PURE Stock News HeadlinesPURE Bioscience (OTCMKTS:PURE) Shares Cross Above Two Hundred Day Moving Average - Here's What HappenedOctober 14 at 3:01 AM | americanbankingnews.comPURE Bioscience (OTCMKTS:PURE) Share Price Breaks Above 200-Day Moving Average - Time to Sell?October 6, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Pure Bioscience Inc.August 12, 2026 | marketwatch.comPURE Bioscience Reports Fiscal Third Quarter 2026 Financial ResultsJune 15, 2026 | businesswire.comPurecore Strengthens Technical Advisory Expertise with Nuclear Fuel Cycle and Uranium Enrichment Specialist, Ted Rygas, PhDJune 15, 2026 | globenewswire.comPurecore Announces up to $1.5 Million Non-Brokered Private PlacementJune 5, 2026 | globenewswire.comPurecore Announces Listing on the Frankfurt Stock ExchangeJune 4, 2026 | globenewswire.comSee More Headlines PURE Stock Analysis - Frequently Asked Questions How have PURE shares performed this year? PURE Bioscience's stock was trading at $0.0420 at the beginning of 2026. Since then, PURE stock has increased by 61.7% and is now trading at $0.0679. How were PURE Bioscience's earnings last quarter? PURE Bioscience (OTCMKTS:PURE) released its earnings results on Monday, June, 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company earned $0.51 million during the quarter. How do I buy shares of PURE Bioscience? Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PURE Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that PURE Bioscience investors own include Aurora Cannabis (ACB), Novavax (NVAX), Cresco Labs (CRLBF), Aurora Cannabis (ACB), Canopy Growth (CGC), DraftKings (DKNG) and Broadcom (AVGO). Company Calendar Last Earnings6/15/2026Today10/14/2026Fiscal Year End7/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:PURE CIK1006028 Webwww.purebio.com Phone(619) 596-8600Fax619-596-8790Employees10Year Founded1992Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.40 million Net Margins-109.59% Pretax Margin-65.45% Return on EquityN/A Return on Assets-321.74% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.36 Sales & Book Value Annual Sales$2.20 million Price / Sales4.01 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-1.36Miscellaneous Outstanding Shares130,018,000Free Float83,784,000Market Cap$8.83 million OptionableNot Optionable Beta0.33 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:PURE) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PURE Bioscience Please log in to your account or sign up in order to add this asset to your watchlist. Share PURE Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
